Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
EBON · Nasdaq · United States · Security & Commodity Brokers, Dealers, Exchanges & Services
In shortEbang International Holdings Inc. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it. Bank or insurer: tests that do not apply to them are left out.
| Operating marginShare of each sale left after running the business, before interest and tax. | -387.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -215.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -5.6% | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -207.2% | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | n/a |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 96.2% | 0/100 |
| Operating margin volatility | 427.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -41.3% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 51 | 32 | 4.9 | 5.9 | 6.5 |
| Cost of revenue | 22 | 17 | 22 | 4.7 | 6.1 |
| Gross profit | 29 | 15 | (17) | 1.2 | 0.4 |
| Research & development | 6.6 | 5.1 | 7.4 | 5.4 | 4.1 |
| Operating income | 2 | (48) | (54) | (30) | (25) |
| Interest expense | 0 | – | – | – | – |
| Pre-tax income | 2.4 | (46) | (39) | (21) | (14) |
| Income tax | (0.4) | (0.1) | (1) | (0) | (0.3) |
| Net income | 4.4 | (44) | (37) | (20) | (14) |
| Diluted EPS | $0.75 | −$7.03 | −$5.86 | −$3.22 | −$2.24 |
| Diluted shares (millions) | 5.9 | 6.2 | 6.3 | 6.3 | 6.3 |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: the model does not apply to banks and insurers.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 24, 2026